LISATA THERAPEUTICS, INC.

Listed Company

LSTACIK 0000320017NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$170.0K

Net Income

$-16.59M

Total Assets

—

Equity

—

Shares Out

9.11M

Op. Cash Flow

$-15.95M

LSTA$3.56+46.50% · past yearDBEQ Basic

Daily closing prices

Business

Lisata Therapeutics is a clinical-stage pharmaceutical company developing certepetide, an investigational peptide therapeutic designed to enhance delivery of anti-cancer drugs to solid tumors via the C-end rule active transport mechanism. The company's lead product candidate is being evaluated in multiple Phase 2 clinical trials for pancreatic cancer, cholangiocarcinoma, and other solid tumors, both as a co-administered agent with chemotherapy and immunotherapy and as a potential conjugate with other therapeutics. Lisata is pursuing partnerships to expand the CendR Platform to additional cancer treatment modalities and diagnostic applications globally.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	200,000	1	0	—	—
Research and development	8	11	13	13	18
General and administrative	10	12	13	—	—
Operating expenses	18	23	26	58	29
Operating loss	−18	−22	−26	−58	−29
Investment income, net	806,000	2	3	1	151,000
Other expense, net	−145,000	−257,000	−186,000	−155,000	−75,000
Total other income	661,000	2	3	897,000	76,000
Net loss before benefit from income taxes and noncontrolling interests	−18	−21	−23	−57	−29
Benefit from income taxes	−962,000	−798,000	−2	−2	−2
Net loss	−17	−20	−21	−54	−27
Less - net income (loss) attributable to noncontrolling interests	0	0	0	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	−17	−20	−21	−54	−27
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)	−1.91	−2.4	−2.58	−10.47	−7.45
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)	−1.91	−2.4	−2.58	−10.47	−7.45
Basic (in shares)	9	8	8	5	4
Diluted (in shares)	9	8	8	5	4

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	16	23	32	25
Marketable securities	0	15	28	37	70
Accounts receivable	0	900,000	0	—	—
Prepaid and other current assets	2	2	3	3	1
Total current assets	18	35	54	72	96
Property and equipment, net	18,000	72,000	175,000	296,000	62,000
Acquired license-intangible, net	0	192,000	263,000	—	—
Other assets	23,000	160,000	332,000	528,000	764,000
Total assets	18	35	55	73	97
Accounts payable	1	1	2	3	2
Accrued liabilities	2	4	4	4	3
Total current liabilities	3	6	7	6	5
Other long-term liabilities	72,000	72,000	210,000	327,000	485,000
Total liabilities	3	6	7	7	5
Commitments and Contingencies (Note 14)	—	—	—	—	—
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,834,613 and 8,409,582 shares, at December 31, 2025 and December 31, 2024, respectively; and outstanding, 8,833,875 and 8,408,844 shares, at December 31, 2025 and December 31, 2024, respectively	9,000	8,000	8,000	8,000	4,000
Additional paid-in capital	580	578	577	575	546
Treasury stock, at cost; 738 shares at December 31, 2025 and December 31, 2024 respectively	−708,000	−708,000	−708,000	−708,000	—
Accumulated deficit	−565	−548	−528	−507	−453
Accumulated other comprehensive loss	−37,000	−81,000	−42,000	−29,000	−70,000
Total Lisata Therapeutics, Inc. stockholders' equity	15	30	48	67	92
Non-controlling interests	−254,000	−254,000	−254,000	−254,000	−254,000
Total equity	15	29	48	66	92
Total liabilities, non-controlling interests and stockholders' equity	18	35	55	73	97

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	1	2	2	—	—
Depreciation and amortization	100,000	200,000	200,000	—	55,000
Loss from equity method investment	0	100,000	0	—	—
Impairment of non-financial asset	100,000	0	—	—	—
Amortization/accretion on marketable securities	−75,000	−455,000	−960,000	788,000	3
Allowance for credit losses	500,000	0	—	—	—
Accounts receivable	401,000	−900,000	0	—	—
Prepaid and other current assets	742,000	852,000	−824,000	−845,000	−453,000
Other assets	140,000	170,000	274,000	237,000	−150,000
Accounts payable, accrued liabilities and other liabilities	−3	−995,000	88,000	−223,000	1
Net cash used in operating activities	−16	−19	−20	−21	−22
Purchase of marketable securities	−9	−56	−98	−90	−180
Sales of marketable securities	24	69	109	122	125
Investment in Impilo Therapeutics	0	−130,000	0	—	—
Purchases of property and equipment	−28,000	0	0	−285,000	−60,000
Net cash provided by investing activities	15	13	10	29	−55
Proceeds from exercise of options	8,000	0	155,000	0	24,000
Tax withholding payments on net share settlement equity awards	−253,000	−274,000	−91,000	−267,000	−248,000
Net proceeds from issuance of common stock	844,000	68,000	321,000	43,000	86
Net cash provided by (used in) financing activities	599,000	−206,000	385,000	−224,000	85
Effect of exchange rate changes on cash	11,000	−55,000	−16,000	−10,000	0
Net decrease in cash and cash equivalents	−253,000	−6	−10	8	8

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is LISATA THERAPEUTICS, INC.'s CIK number?

LISATA THERAPEUTICS, INC.'s SEC CIK number is 0000320017 (320017). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find LISATA THERAPEUTICS, INC.'s SEC filings?

All of LISATA THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did LISATA THERAPEUTICS, INC. last report earnings?

LISATA THERAPEUTICS, INC. (LSTA) most recently filed an earnings 8-K with the SEC on Nov 6, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000320017-25-000069). This is LISATA THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is LISATA THERAPEUTICS, INC.'s most recent earnings 8-K?

LISATA THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed Nov 6, 2025 under accession 0000320017-25-000069. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View LISATA THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →